Authors
No takes yet. Share an insight, caveat, or question.
Sympathetic hyperactivity in CKD contributes to cardiovascular and renal damage, suggesting a potential role for targeted anti-adrenergic therapies such as beta-blockers or centrally acting sympatholytics in addition to ACE inhibitors or ARBs.
P. J. Blankestijn (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: